ANTHEM Anthem Biosciences Q1 FY27 results (Apr–Jun 2026) and concall
Anthem Biosciences Limited reported Q1 FY27 consolidated revenues of Rs. 418 crores, with strong EBITDA and PAT margins of 39.6% and 27.1% respectively. Despite a softer Q1 due to timing shifts in deliveries, the company remains confident in achieving its full-year growth targets, supported by a 60% order book visibility and the addition of a new Big Pharma customer. The company is also progressing with its Unit 4 expansion, targeting commissioning by end of FY28 with a FY27 capex of Rs. 700 crores.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue down 28.6%, net profit down 31.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 525 | 498 | 479 | 538 | 552 +5% | 417 −16% | 582 +22% | 384 −29% |
| EBITDA | 201 | 167 | 198 | 195 | 226 +12% | 163 −2% | 267 +35% | 131 −33% |
| Net profit | 170 | 128 | 123 | 148 | 198 +16% | 112 −12% | 212 +72% | 102 −31% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
